Sickle cell anemia (SCA) and its complications result in significant morbidity and mortality, posing a significant public health challenge worldwide. SCA and its societal costs disproportionally affect Africa. A strong geographical link between the highest HbS allele frequencies and high malaria endemicity was observed at the global scale, but this observation is influenced primarily by the relationship found in Africa.[@b1-mjhid-9-1-e2017030] Nigeria, in particular, has the largest population of children and adults with SCA in the world. Approximately 150,000 children are born with SCA each year in Nigeria, compared to approximately 1,100 children born in the US each year. A greater understanding of the pulmonary factors contributing to morbidity and mortality among children with SCA may lessen the public health burden of SCA worldwide.

The prevalence of asthma in patients with SCA is higher than in normal population (30--70% versus 20%).[@b2-mjhid-9-1-e2017030] Asthma increases the risk of morbidity and mortality in patients with SCA.[@b3-mjhid-9-1-e2017030] It has been shown that there is an association between the presence of bronchial hyperactivity and the onset of acute chest syndrome (ACS):[@b3-mjhid-9-1-e2017030]--[@b11-mjhid-9-1-e2017030] children with SCA and asthma have more frequent episodes of ACS and/or veno-occlusive crisis (VOC). Asthma is also a risk factor for early second hospitalization after discharge from hospital.[@b12-mjhid-9-1-e2017030] Therefore, it seems that asthma is an additional factor that aggravates some manifestations of SCA.

Often in a patient with SCA, it is difficult to distinguish from the beginning the symptoms of an asthma attack from that of an initial ACS. Children with SCA are prone to invasive infections caused by *S. pneumonia*, *H. influenzae,* and *Plasmodium falciparum*. Like thalassemia, allogeneic hematopoietic stem cell transplantation (HSCT) is curative in most individuals with SCA.[@b13-mjhid-9-1-e2017030] We analyzed pulmonary function in SCA patients underwent BMT through high-resolution computed tomography (HRCT) scan and spirometry, before and after transplant.

This study included 37 consecutive SCA patients who underwent bone marrow transplantation from human leukocyte antigen (HLA)-identical sibling donors between 2010 and 2015 following a myeloablative conditioning regimen. The patients were referred to Mediterranean Institute of Hematology for transplantation, and none of them were followed previously in Italy. The median patient age was 10 years (range 2--17 years). Patient characteristics at the time of transplantation are summarized in [Table 1](#t1-mjhid-9-1-e2017030){ref-type="table"}. Patients Lansky/Karnofsky performance score varied between 90--100% at the time of transplantation. None of these patients had a splenectomy before transplantation. Only two patients received chronic blood transfusions, and the serum ferritin level before transplantation was 278 ± 231 ng/mL (mean ± SD). Before transplantation, eighteen patients had recurrent, painful, vaso-occlusive crisis (VOC); thirteen patients had VOC in association with acute chest syndrome (ACS); five patients experienced ischemic stroke with or without association with VOC; two patients exhibited leukocytosis, and dactylitis and one patient exhibited priapism. Twelve patients were on hydroxyurea therapy before transplantation. Repeated and severe VOC, stroke, acute chest syndrome, in association with a not easy availability of hydroxyurea and/or transfusion therapy in their Country, were indications for HSCT. The patients were subjected to instrumental examinations in pre-transplant phase with HRCT and spirometry. Patients received fludarabine (30 mg/m^2^/d) for 5 days followed by conditioning regimen including targeted intravenous busulfan and cyclophosphamide (200 mg/kg total dose). They received cyclosporine A, low-dose methylprednisolone, and a short course of methotrexate as graft-versus-host disease (GVHD) prophylaxis. All patients received BM from HLA-identical sibling donors 36 h after the final dose of cyclophosphamide. HRCT scan revealed parenchymal consolidation with nodular thickening in 19 out 37 patients, as active or residual pneumonia. Twenty-five out 37 patients had evaluable standard spirometry before transplantation. The following parameters were included: forced vital capacity, forced expiratory volume in the first second (FEV1), the ratio FEV1/FVC, and the total lung capacity (TLC). Spirometry results (FVC, FEV~1~, FEV~1~/FVC, TLC) were expressed as percent of the predicted value based on gender, age, and ethnic appropriate reference standards. Spirometry was performed according to standard protocols using European Respiratory Society/American Thoracic Society acceptability and repeatability criteria, adapted for children where appropriate (normal value: FVC\>75; FEV~1~/FVC\>80).[@b14-mjhid-9-1-e2017030] Eleven out of 25 patients had a restrictive respiratory pattern (FVC \<75%), one patient had a restrictive/obstructive pattern (FVC \<75% and FEV~1~/FVC \<80%) and 13 of 25 patients had normal respiratory function tests. Six out 12 patients with restrictive respiratory pattern had ACS and bronchial hyperactivity ([Table 1](#t1-mjhid-9-1-e2017030){ref-type="table"}). All 37 patients had sustained engraftment after transplant. After 3--6 months of transplantation, we found no significant changes in spirometry values ([Table 2](#t2-mjhid-9-1-e2017030){ref-type="table"}). In particular, four out of nine patients had unchanged respiratory pattern, three patients experienced worsening, probably due to post-transplant infectious complications and/or the occurrence of acute GVHD (UPN 207, acute GVHD; UPN 213 and UPN 234, *Aspergillus fumigatus* pneumonia; UPN 237, *Klebsiella pneumonia* pneumonia) and two patients showed an initial amelioration.

Pulmonary complications are leading causes of morbidity and mortality in SCA.

Airway obstructions and repeated pulmonary infections are among the primary causes of pulmonary involvement, and they result in obstructive or restrictive respiratory disorders, which can result in pulmonary hypertension. Moreover, this population often presents with acute chest syndrome, which is characterized by chest pain, prostration, cough, dyspnea and hypoxia.[@b2-mjhid-9-1-e2017030]

When assessing pulmonary function, individuals may exhibit either normal function or altered ventilatory patterns, which are classified as obstructive, restrictive or mixed. Obstructive ventilatory patterns (OVPs) are characterized by disproportionately decreased peak flows (PEF) when compared to the volume that can be eliminated, and the FEV~1~ and FEV~1~/FVC are the major measures by which to characterize OVPs. Restrictive pulmonary patterns (RVPs) are characterized by decreased FVC. It should be noted that RVP cannot be measured by spirometry. However, RVP values can be inferred when the vital capacity (VC) and FVC are decreased, and the FEV~1~/FVC ratio is normal or increased. Finally, mixed ventilatory pattern (MVP) is characterized by having both obstruction and restriction simultaneously. In the present study, the lung function tests (LFTs) obtained from 48% of the patients revealed changes in the pulmonary function (i.e., RVP or MVP). Our results indicate that RVP is a common finding in this disease. The presence of RVP in this population might result from episodes of vaso-occlusion in the lung, which is an organ that is prone to suffer from this condition because of its anatomical characteristics. This can result in pulmonary infarctions, necrosis of the alveolar wall with consequent airway remodeling, pulmonary fibrosis and progressive loss of lung function. In addition, RVP may be a result of fibrosis after many infection diseases in pulmonary districts.[@b15-mjhid-9-1-e2017030] In fact, the HRCT often in these patients showed fibrotic outcomes, expression of recent or past lung infections. RVP has been observed in our patients with bronchial hyperactivity instead of a typical asthma attack. Airway hyper-responsiveness is another feature of sickle cell lung disease. Various studies have defined hyper-responsiveness either as a decrease in lung function after exercise, cold air, or methacholine challenges or increase after administration of a bronchodilator and up to 70% of children with sickle cell disease have airway hyperresponsiveness.[@b4-mjhid-9-1-e2017030] After 3--6 months of transplant, we do not observe significant changes in spirometry value. In such a short time from the transplant, lung function may still be influenced by infectious events during transplant or the possible occurrence of acute GVHD. Our findings indicate that routine spirometry, before and after transplantation, is an important adjunct to the clinical in this patient population with a high prevalence of pulmonary disease and lung dysfunction.
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###### 

Spirometry in SCA patients before transplant. The standard spirometry was performed according to the Guidelines of American Thoracic Society/European Respiratory Society (ATS/ERS 2005 and Gold 2009). Normal value: FVC\>75% of theoric value; FEV1/FVC\>80%; TLC \>80%. In bold are reported the SCA patients with restrictive respiratory pattern, ACS and bronchial hyperactivity.

  UPN.      Age/Sex    HbS pre TMO   Clinical conditions   Spirometry pre TMO                               
  --------- ---------- ------------- --------------------- -------------------- -------- --------- -------- -------
  **166**   **14/M**   **76**        **VOC ACS Stroke**    **58**               **64**   **100**   **62**   **R**
  191       6/F        70            VOC ACS               //                   //       //        //       n.e
  **192**   **9F**     **75**        **VOC ACS**           **67**               **59**   **83**    **63**   **R**
  **195**   **11/F**   **71**        **VOC ACS Stroke**    **65**               **65**   **96**    **72**   **R**
  199       15/F       86            VOC ACS               86                   78       86        101      N
  201       17/M       89            VOC                   //                   //       //        //       n.e
  202       3/M        85            VOC                   //                   //       //        //       n.e
  204       12/M       92            VOC                   64                   45       100       75       R
  205       5/M        79            VOC                   //                   //       //        //       n.e
  206       7/F        83            VOC                   //                   //       //        //       n.e
  207       13/M       88            VOC ACS               76                   68       81        103      N
  210       3/M        73            VOC Stroke            //                   //       //        //       n.e
  213       16/M       91            VOC                   82                   76       85        89       N
  215       2/M        87            Dactylitis            //                   //       //        //       n.e
  **216**   **14/F**   **92**        **VOC ACS**           **62**               **54**   **82**    **72**   **R**
  219       15/M       91            VOC                   59                   50       78        62       O/R
  221       4/F        83            VOC                   //                   //       //        //       n.e
  222       16/M       91            VOC                   49                   45       86        70       R
  224       5/F        61            VOC ACS               //                   //       //        //       n.e
  **229**   **17/M**   **82**        **VOC ACS**           **52**               **51**   **89**    **62**   **R**
  231       5/M        88            Stroke                //                   //       //        //       n.e
  **234**   **15/F**   **94**        **VOC ACS**           **57**               **51**   **86**    **64**   **R**
  235       8/F        77            Stroke                //                   //       //        //       n.e
  236       17/M       63            Priapism              82                   75       83        95       N
  237       10/F       85            VOC                   87                   85       89        93       N
  239       13/F       73            VOC                   71                   68       90        70       R
  240       12/F       80            VOC                   72                   67       88        69       R
  252       8/F        88            VOC                   65                   55       82        68       R
  258       17/M       79            VOC ACS ABN           83                   76       84        92       N
  261       4/M        80            VOC                   93                   79       97        93       N
  263       8/M        78            VOC                   70                   72       94        90       N
  271       5/M        80,9          VOC                   80                   73       95        93       N
  273       13/M       91,5          VOC                   66                   71       97        92       N
  285       12/M       79,7          VOC                   93                   79       97        94       N
  289       17/M       84,7          VOC + ACS             86                   78       86        93       N
  291       14/M       70,2          VOC + ACS             85                   79       85        95       N
  297       2/M        63,4          VOC + dactylitis      //                   //       //        //       n.e

*Abbreviations:* UPN, unique patient number; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; TLC, total lung capacity; n.e, not evaluable; O, Obstructive ventilatory pattern; R, Restrictive ventilatory pattern; HbS, hemoglobin S; VOC, vaso-occlusive crisis; ACS, acute chest syndrome; ABN, avascular bone necrosis.

###### 

Spirometry in SCA patients post transplant. The standard spirometry was performed after 3--6 months of transplant.

  UPN.   Age/Sex   Spirometry pre-TMO   Spirometry post-TMO                                          
  ------ --------- -------------------- --------------------- ----- ----- ----- ---- ---- ---- ----- -----
  166    14/M      58                   64                    100   62    R     57   61   97   64    R
  207    13/M      76                   68                    82    103   N     72   59   75   100   N/O
  213    16/M      82                   76                    85    89    N     68   72   84   89    N/R
  219    15/M      59                   50                    78    62    O/R   59   55   85   80    R
  229    17/M      52                   51                    89    62    R     54   54   91   80    R
  234    15/F      57                   51                    86    64    R     54   54   91   80    R
  236    17/M      82                   75                    83    95    N     83   74   83   95    N
  237    10/F      87                   85                    89    93    N     52   57   92   83    R
  239    13/F      71                   68                    90    70    R     79   76   91   85    N

*Abbreviations:* UPN, unique patient number; FVC, forced vital capacity; FEV1, forced expiratory volume in one second; TLC, total lung capacity; O, Obstructive ventilatory pattern; R, Restrictive ventilatory pattern.
